Evolving Response Criteria for Tumor Evaluation in Oncology Clinical Trials

| March 3, 2014

article image
Rapid advances in imaging and cancer biomarkers are helping to shift treatments from cytotoxic to molecularly targeted therapies, necessitating modifications to conventional anatomical response criteria. Newer response criteria take into account parameters such as tumor metabolism, proliferation, lipid turnover, hypoxia and other characteristics of specific cancer types, providing clinicians with enhanced tools for the proper categorization of tumor responses.

Spotlight

Takeda Oncology

Takeda Oncology is a leading biopharmaceutical company focused on oncology that combines the agility, ideals and camaraderie of a start-up with the resources of Japan’s largest pharmaceutical company. The result is a creative, entrepreneurial environment where quality science and making a difference in patients'​ lives are the priorities.

OTHER ARTICLES

WANT LESS “LIABILITY” AND MORE “RELIABILITY” FROM YOUR CLINICAL MOBILITY SOLUTION?

Article | March 2, 2020

I recently discussed the different ways that consumer-grade smartphones can compromise patients’ health, safety and overall care. However, some clinicians and healthcare administrators have indicated in recent months that they need help selecting the right enterprise-grade mobility solutions for their unique operating models and workflows. There are many different hardware and software options, and a single rugged device can come in multiple configurations. So, how do you know if you’re picking the right communication tools for your clinicians? The key is to first set performance expectations for the total mobility solution rather than the device alone.

Read More

Artificial intelligence in pharma: utilising a valuable resource

Article | March 2, 2020

The pharmaceutical industry is set to greatly benefit from the use of artificial intelligence (AI), due to its wide range of applications. Sydney Tierney discusses how machine learning can enhance marketing, manufacturing and drug trials. Artificial intelligence (AI) can be applied to nearly every aspect of the pharmaceutical and healthcare industry, to enhance data processing. Adopting the technology will reveal the astonishing potential of the healthcare sector, with success rates flying higher than ever before – especially in the research and development of crucial, life-changing drugs.

Read More

Top Pharmaceutical Firms Urge FDA to Adopt Blockchain for Drug Tracking

Article | March 2, 2020

Leading market participants in the United States pharmaceutical industry, logistics firms, distributors and other stakeholders in the pharma supply chain have come together to publish a report buttressing the need for industry players to adopt blockchain for tracking prescription drugs, following the successful completion of a DLT pilot project with the Food and Drug Administration (FDA), according to reports on February 24, 2020. Though nascent, blockchain technology, the building blocks of Bitcoin (BTC) and other cryptocurrencies are fast gaining ground across various ecosystems, due to its immutability, security, privacy, and other intricate properties. In the latest development, 25 leading manufacturers of pharmaceutical products, logistics partners and other market participants in the pharma supply chain, have published a report that highlights the importance of blockchain technology in drug traceability.

Read More
PHARMACY MARKET

A pharma outsourcing mission

Article | March 2, 2020

In a way, getting through the initial stages of a complex pharmaceutical project that is being outsourced to a contract development and manufacturing organization is like getting a rocket off the ground. Many drug developers express frustration with the time it often takes during the initial stages of working with a CDMO — from the time they first reach out to a CDMO for help until they receive a proposal. Some have described it as months of silence from when they send a request for proposal (RFP) until they have a proposal in hand. The initial stages of a relationship between drug sponsor and CDMO often do not get the attention it deserves, and valuable time is lost, delaying projects and delaying delivery of therapeutics to patients. The quick scheduling of the ACT meeting with the right attendees can deliver immediate answers to key questions needed by the drug sponsor for effective planning and can help propel projects to a successful launch.

Read More

Spotlight

Takeda Oncology

Takeda Oncology is a leading biopharmaceutical company focused on oncology that combines the agility, ideals and camaraderie of a start-up with the resources of Japan’s largest pharmaceutical company. The result is a creative, entrepreneurial environment where quality science and making a difference in patients'​ lives are the priorities.

Events